Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Bank of America (1)
- Bernanke (1)
- Bio-pharmas (1)
- Corporate governance (1)
- Daubert v. Merrell Dow Pharmaceuticals (1)
-
- Drug and Cosmetic Act of 1938 (1)
- FRCP 54 (1)
- FRE 706 (1)
- Federal Food (1)
- Financial crisis (1)
- Food & Drug Administration (1)
- Ken Lewis (1)
- Market crash (1)
- Merrill Lynch (1)
- Paulson (1)
- Regulation of pharmaceutical and medical devices (1)
- Rule 10b-5 (1)
- Section 122(12) (1)
- Securities class actions (1)
Articles 1 - 2 of 2
Full-Text Articles in Securities Law
Fiduciary Exemption For Public Necessity: Shareholder Profit, Public Good, And The Hobson's Choice During A National Crisis, Robert J. Rhee
Fiduciary Exemption For Public Necessity: Shareholder Profit, Public Good, And The Hobson's Choice During A National Crisis, Robert J. Rhee
UF Law Faculty Publications
This Article is written as two discrete, independently accessible topical sections. The first topical section, presented in Part I of this Article, is a case study of Bank of America’s acquisition of Merrill Lynch and the impact of a flawed merger execution on the board’s subsequent decisions. The second topical section, presented Parts II-IV of this Article, advances a theoretical basis for fiduciary exemption during a public crisis. The financial crisis of 2008 was the worst economic disaster since the Great Depression. It nearly resulted in a collapse of the global capital markets. A key event in the history of …
The Sitting Ducks Of Securities Class Action Litigation: Bio-Pharmas And The Need For Improved Evaluation Of Scientific Data, Stuart R. Cohn, Erin M. Swick
The Sitting Ducks Of Securities Class Action Litigation: Bio-Pharmas And The Need For Improved Evaluation Of Scientific Data, Stuart R. Cohn, Erin M. Swick
UF Law Faculty Publications
Rule 10b-5, a powerful weapon against any publicly-listed company whose share price drops on adverse news, is particularly skewed against pharmaceutical and other bio-technology companies (bio-pharmas). It is not a coincidence that there is a disproportionate number of class actions filed against bio-pharmas. The volume and complexity of data underlying most bio-pharma cases create enormous outcome uncertainties, settlement pressures, and potentially huge contingent liabilities over substantial periods of time. The vulnerability and risks that bio-pharmas face in Rule 10b-5 class actions are unique among all publicly-traded industries, yet many cases proceed along traditional grounds without courts employing either their statutory …